Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 17/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.39 |
| ▸ | CDK9 | P50750 | 6/20 | 0.39 |
| ▸ | CCNK | O75909 | 4/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.39 |
| ▸ | CDK1 | P06493 | 11/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.38 |
| ▸ | CDK4 | P11802 | 10/20 | 0.38 |
| ▸ | CCND1 | P24385 | 10/20 | 0.38 |
| ▸ | CCND3 | P30281 | 9/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 9/20 | 0.38 |
| ▸ | CDK7 | P50613 | 3/20 | 0.38 |
| ▸ | CCNH | P51946 | 3/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27026916 | 0.87 | CDK2 (0.47) | CDK2CCNE1CCNT1CDK9CCNK | |
| SCHEMBL27026918 | 0.84 | CCNE1 (0.45) | CDK2CCNE1CCNT1CDK9CCNK | |
| SCHEMBL26267828 | 0.84 | CDK2 (0.48) | CDK2CCNE1CCNT1CDK9CDK1 | |
| SCHEMBL26268440 | 0.82 | CDK2 (0.46) | CDK2CCNE1CCNT1CDK9CCNK | |
| SCHEMBL25402180 | 0.82 | CCNE1 (0.51) | CDK2CCNE1CCNT1CDK9CDK1 | |
| SCHEMBL30537166 | 0.82 | CCNE1 (0.51) | CDK2CCNE1CCNT1CDK9CDK1 | |
| SCHEMBL26268447 | 0.81 | CDK2 (0.45) | CDK2CCNE1CCNT1CDK9CDK1 | |
| SCHEMBL26268376 | 0.81 | CDK2 (0.45) | CDK2CCNE1CCNT1CDK9CCNK | |
| SCHEMBL26268656 | 0.79 | CDK2 (0.43) | CDK2CCNE1CCNT1CDK9CCNK | |
| SCHEMBL27026844 | 0.78 | CDK2 (0.48) | CDK2CCNE1CCNT1CDK9CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018136-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-01-18 | — | — | US | disclosed |
| WO-2023172957-A1 | THAIZOLE-PYRIMDIINE CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018136-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CDK2 4/4885CCNE1 36/4885CCNT1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.